Evidence map›Paper›PMID 34688261›Full record

SynthesisBMC infectious diseases2021

Serum CA-125 for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis.

Ping Zhao, Qin Yu, Aijie Zhang, Fang He, Songyan Xu, Liang Chen

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ping ZhaoDepartment of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, NO. 10, Tie Yi Road, Yang Fang Dian, Haidian District, Beijing, 100038, China. zhaoping3240@bjsjth.cn.ORCID http://orcid.org/0000-0002-9929-6053
Qin YuTuberculosis Clinic, Chaoyang District Centre for Disease Control and Prevention, Chaoyang District, Beijing, China.
Aijie ZhangTuberculosis Clinic, Chaoyang District Centre for Disease Control and Prevention, Chaoyang District, Beijing, China.
Fang HeDepartment of Internal Medicine, Shuangqiao Hospital, Beijing, China.
Songyan XuDepartment of Medical Imaging, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing, China.
Liang ChenDepartment of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, NO. 10, Tie Yi Road, Yang Fang Dian, Haidian District, Beijing, 100038, China.
Capital Medical University · CNIntegrated Chinese Medicine (China) · CNXinqiao Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary tuberculosis (PTB) remains the world's deadliest infectious killer. Serum CA-125 test are useful in the diagnosis of PTB. Although studies on the relation between CA-125 and PTB have been reported, the specificity and sensitivity of serum CA-125 in diagnosing PTB vary widely among different studies. The present study was performed to evaluate the accuracy of CA-125 for the diagnosis of PTB via a meta-analysis of data obtained from previous studies.

methodsEnglish and Chinese medical electronic databases were searched for eligible studies published up to February 2020. STATA software was used to obtain a pooled estimation of the diagnostic accuracy of CA-125 and analyze the heterogeneity of the recruited studies. Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used to evaluate the quality of the obtained studies.

resultsA total of 16 articles were included in this study. The pooled sensitivity and specificity of CA-125 were 0.85 [95% confidence interval (CI) 0.75-0.91] and 0.87 (95% CI 0.78-0.93), respectively. Moreover, the pooled positive likelihood ratio (LR+), negative likelihood ratio (LR-), and diagnostic odds ratio (DOR) of CA-125 were 6.65 (95% CI 3.62-12.20), 0.18 (95% CI 0.10-0.31), and 37.82 (95% CI 13.17-108.60), respectively. The area under the summary receiver operating characteristic curve (AUC) was 0.93.

conclusionsTaken together, the results indicate that serum CA-125 presents potential practical value for diagnosing PTB, but its clinical applicability must be further examined.

Indexed as

Tuberculosis, PulmonaryHumansImmunologic TestsOdds RatioROC CurveSensitivity and SpecificityCA-125DiagnosisInfectionMeta-analysisSerologyTuberculosis

Identifiers

PMID34688261
PMCPMC8542302
OpenAlexW3208768457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.